Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 plus carboplatin and bevacizumab in platinum-sensitive recurrent ovarian cancer (Phase Ib/II)
ChiCTR2500109601Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab rezetecan in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 cohorts), sponsored by Tongji Hospital. Primary endpoints: Dose limiting toxicity (DLT), Recommended Phase II dose (RP2D) and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500109601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109601.